Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases
Findings from the phase II study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from the phase II study
Findings from the COMMANDS study
Findings from the TRANSCEND CLL 004 study
Findings from the randomised phase III study
Findings from the CARTITUDE-4 study
Findings from the CONTACT-03 study
Findings from the PHAROS study
New indication concerns a combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence
Findings from the pivotal HERIZON-BTC-01 study
Findings from the TALAPRO-2 study
Evidence for efficacy is based on the results from the PROpel study
Findings from the the window-of-opportunity TOT-HER3 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.